Natco Pharma gets FDA approval for generic Vidaza

SILVER SPRING, Md. — The Food and Drug Administration has approved Natco Pharma’s generic of Celgene and Breckenridge’s Vidaza (azacitidine for injection). The drug is indicated to treat myelodysplastic syndrome.

 

Natco’s generic will be available in a dosage strength of 100 mg per vial. The drug had combined sales of $188 million for the 12 months ended April 2017, the company said.